Latest Imugene News & Updates

See the latest news and media coverage for Imugene. We track all announcements, press releases, and industry mentions in real time, all in one place.

Imugene

Clinical-stage immuno-oncology company

imugene.com

Headquarters: Sydney, Australia
Founded year: 2013
Company type: Public company
Number of employees: 50–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Imugene

In short: Imugene reported high clinical response rates for its azer-cel therapy and secured over $30 million in funding as its long-term CEO resigned.

Company announcements

July 27 Imugene

Imugene reports partial response in lymphoma trial

Both follicular lymphoma patients responded to azer-cel and BTKi therapy after prior relapse.

July 1 Imugene

Imugene's azer-cel trial yields complete responses

Both evaluable patients in the BTKi cohort responded, including the first Mantle Cell Lymphoma patient after BTKi resistance.

June 23 Imugene

Imugene's azer-cel achieves key clinical milestones

Two FDA Fast Track Designations and first patient dosed in combination cohort for B-cell cancers.

June 22 Imugene

Imugene's azer-cel gets FDA fast track, 100% CLL response

The FDA granted fast track for CLL/SLL and MZL. Updated ASCO data showed 83% MZL and 100% CLL response rates. First patient dosed in BTKi combo cohort.

Media coverage

July 27 Herald Sun

Imugene (ASX:IMU): Biotech Stock Rockets as FDA Fast Track News Ignites Investor Excitement

Imugene (ASX:IMU): Biotech Stock Rockets as FDA Fast Track News Ignites Investor Excitement...

Never miss news about Imugene

Track Imugene and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Imugene competitors & trending companies

Browse news for competitors to Imugene and other trending companies.